{"disease":{"id":"vasodilatory-shock","name":"vasodilatory shock"},"drugs":{"marketed":[{"drug_id":"vasopressin","indication_name":"Vasodilatory Shock Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VASOPRESSIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03378466","title":"Heparin Anticoagulation in Septic Shock","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":178,"lead_sponsor_name":"University of Manitoba","has_results":false},{"nct_id":"NCT06953297","title":"Vasopressin Use in Septic Shock From Türkiye","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Karadeniz Technical University","has_results":false},{"nct_id":"NCT05824767","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT03245528","title":"Expanded Access for LJPC-501","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"La Jolla Pharmaceutical Company","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}